 Connection
Carlo Marchetti to Inflammasomes
This is a "connection" page, showing publications Carlo Marchetti has written about Inflammasomes.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.873 |
|
|
|
-
Marchetti C. The NLRP3 Inflammasome as a Pharmacological Target. J Cardiovasc Pharmacol. 2019 10; 74(4):285-296.
Score: 0.640
-
Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, de Graaf DM, Dinarello CA, Joosten LAB. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther. 2018 08 03; 20(1):169.
Score: 0.591
-
Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, Carta S, Tengesdal I, Nemkov T, D'Alessandro A, Henry C, Jones GS, Goodrich SA, St Laurent JP, Jones TM, Scribner CL, Barrow RB, Altman RD, Skouras DB, Gattorno M, Grau V, Janciauskiene S, Rubartelli A, Joosten LAB, Dinarello CA. OLT1177, a ?-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018 02 13; 115(7):E1530-E1539.
Score: 0.570
-
Marchetti C, Mezzaroma E, Toldo S. Effects of dimethyl sulfoxide on the NLRP3 inflammasome. Immunobiology. 2015 Aug; 220(8):1030.
Score: 0.466
-
Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, Federici M, Van Tassell BW, Zhang S, Abbate A. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014 Apr; 63(4):316-322.
Score: 0.437
-
Tengesdal IW, Dinarello CA, Marchetti C. NLRP3 and cancer: Pathogenesis and therapeutic opportunities. Pharmacol Ther. 2023 Nov; 251:108545.
Score: 0.212
-
Lonnemann N, Hosseini S, Marchetti C, Skouras DB, Stefanoni D, D'Alessandro A, Dinarello CA, Korte M. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2020 12 15; 117(50):32145-32154.
Score: 0.174
-
Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020 04 24; 126(9):1260-1280.
Score: 0.166
-
Valle Raleigh J, Mauro AG, Devarakonda T, Marchetti C, He J, Kim E, Filippone S, Das A, Toldo S, Abbate A, Salloum FN. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res. 2017 May 01; 113(6):609-619.
Score: 0.135
-
Toldo S, Marchetti C, Abbate A. Re. "NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective". Biochem Biophys Res Commun. 2016 Feb 19; 470(4):811-2.
Score: 0.124
-
Toldo S, Mezzaroma E, McGeough MD, Pe?a CA, Marchetti C, Sonnino C, Van Tassell BW, Salloum FN, Voelkel NF, Hoffman HM, Abbate A. Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc Res. 2015 Feb 01; 105(2):203-12.
Score: 0.115
-
Mezzaroma E, Marchetti C, Toldo S. Letter by Mezzaroma, et al regarding article, "NLRP3 inflammasome as a therapeutic target in myocardial infarction". Int Heart J. 2014; 55(4):379.
Score: 0.111
-
Toldo S, Mezzaroma E, Van Tassell BW, Farkas D, Marchetti C, Voelkel NF, Abbate A. Interleukin-1? blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol. 2013 Mar; 98(3):734-45.
Score: 0.100
-
Toldo S, Marchetti C, Mauro AG, Chojnacki J, Mezzaroma E, Carbone S, Zhang S, Van Tassell B, Salloum FN, Abbate A. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. Int J Cardiol. 2016 Apr 15; 209:215-20.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|